REPLIGEN CORP

Repligen was founded in 1981 by Alexander Rich and Paul Schimmel and was incorporated in Delaware. It has a headquarters and manufacturing facility in Waltham, Massachusetts.

In 2008, an agreement was struck to divest certain intellectual property rights to Bristol-Myers Squibb around the drug Orencia in exchange for ongoing royalty payments through the end of 2013.

In 2011, Repligen acquired bioproduction assets from Novozymes, which doubled the company's bioprocessing capabilities.

Before 2012, Repligen maintained dual capabilities in developing pharmaceutical therapeutics (drug discovery and development) and the development of materials supporting biological drug manufacture (bioprocessing business). A decision was made in 2012 to focus on the bioprocessing business and reduce research and development expenditures.

Development of an imaging agent, designated RG1068, based on a synthetic human hormone was halted in 2012 following a request by the FDA for additional safety and efficacy data beyond that provided in a New Drug Application submission; a marketing authorisation application had been submitted in parallel to the EMA.

At the end of 2012, Repligen out-licensed its spinal muscular atrophy program, in particular the small molecule candidate drug RG3039, to Pfizer. This divestment included licensing rights to two patents to Pfizer.

At the start of 2014, the company out-licensed its Friedreich's ataxia program, including a library of histone deacetylase inhibitor compounds, to BioMarin Pharmaceutical for US$ 2,000,000 and future milestone and royalty payments.

Repligen has made several acquisitions through the early 2020s, including BioFlex Solutions and Tantti Laboratory Inc. among others.

As of 2024 [update], the company's President and Chief Executive Officer is Olivier Loeillot.

As of 2025 it employs approximately 2,000 employees across several sites in the United States, Europe, and Asia.